Studying why chronic inflammatory skin diseases differ between patients over time
Observes patients with several chronic inflammatory skin diseases to find factors shaping their course.
Plain-language title generated from the registry record
Registry title: Determinants of Chronic Inflammatory Skin Disease Trajectories
Key facts
- Where
- Kiel, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a long-lasting inflammatory skin disease diagnosed by a dermatologist. Researchers will follow them over time and study their samples.
- Age
- 0 Years to 80 Years
- Sex
- All sexes can join.
- Disease stage
- Inflammatory skin disease diagnosed by a dermatologist.
- Earlier treatment
- No systemic immunosuppressive therapy or phototherapy in the last 4 weeks. No biologics therapy (e.g. dupilumab, tralokinumab) in the last 3 months. No topical corticosteroids, calcineurin inhibitors or emollients on the target skin areas 24 hours before sample collection.
Main reasons for not taking part
- Cannot give written informed consent (or the legal guardian cannot)
- Pregnant or breastfeeding women
- Taking part in another clinical trial at the same time
- Recent systemic immunosuppressive therapy, phototherapy or biologics therapy
- Topical treatment of the target skin areas in the 24 hours before sample collection
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 80 years old?
Source: NCT05928169, who can take part
Where in Germany
- Department of Dermatology and Allergy, University Hospital Schleswig-HolsteinKiel, GermanyContact: Stefanie SieversTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital Schleswig-Holstein
- Trial code
- NCT05928169
- Record updated
- 28 August 2026
- Original description
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.Read full original descriptionShow less
Determinants of Chronic Inflammatory Skin Disease Trajectories
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.
Inclusion: dermatologist-diagnosed inflammatory skin disease; informed consent.
Exclusion: concurrent participation in a clinical trial; use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months; treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection; subject and/or the legal guardians are not able to give written informed consent; pregnant and breastfeeding women.